NCD On ESAs In Renal Setting Opposed By Physicians, Patients, And Amgen
Executive Summary
Amgen is being joined by industry and patient advocacy groups in calling on CMS to back away from considering a national coverage determination for Medicare Part B reimbursement of erythropoiesis-stimulating agents in the renal setting until data suggests a need for closer examination
You may also be interested in...
MedCAC To Examine ESAs In Chronic Kidney Disease, Pharmacogenomic Testing In Cancer
The usage of erythropoiesis stimulating agents outside the renal setting is already subject to coverage limitations in Medicare.
As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears
Amgen could be facing a new threat on the reimbursement front just days after celebrating the removal of several "major overhangs" to its erythropoiesis-stimulating agents during its second quarter earnings call
FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.